International Multi-center Double-blind Comparative Randomized Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 (JSC "BIOCAD", Russia) 120 mcg or 180 mcg Intramuscularly, Biweekly and Avonex (Biogen Idec Limited, Great Britain) 30 mcg, Weekly, for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

Trial Profile

International Multi-center Double-blind Comparative Randomized Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 (JSC "BIOCAD", Russia) 120 mcg or 180 mcg Intramuscularly, Biweekly and Avonex (Biogen Idec Limited, Great Britain) 30 mcg, Weekly, for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Peginterferon beta-1a (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Biocad
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top